SCHEMBL1815975

SCHEMBL1815975

COc1ccc(-c2csc(C(N)=NO)n2)cc1OC

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 10/20 0.53
KMT2A Q03164 9/20 0.53
ALDH1A1 P00352 4/20 0.53
MAPK1 P28482 2/20 0.53
ALOX15 P16050 1/20 0.53
HSD17B10 Q99714 1/20 0.53
PKM P14618 1/20 0.52
MAPT P10636 8/20 0.51
RAB9A P51151 5/20 0.51
NPC1 O15118 4/20 0.51
SMN1; SMN2 Q16637 4/20 0.51
HTT P42858 2/20 0.51
KDM4E B2RXH2 1/20 0.51
PLAU P00749 2/20 0.50
THRB P10828 2/20 0.49
TP53 P04637 1/20 0.49
GAA P10253 2/20 0.49
RECQL P46063 1/20 0.49
GFER P55789 1/20 0.49
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8328119 1.00 MEN1 (0.53) MEN1KMT2AALDH1A1MAPK1ALOX15
SCHEMBL7434688 0.91 GAA (0.62) MEN1KMT2AALDH1A1MAPK1ALOX15
SCHEMBL6687492 0.83 MEN1 (0.62) MEN1KMT2AALDH1A1MAPK1ALOX15
SCHEMBL7435769 0.83 MAPT (0.60) MEN1KMT2AALDH1A1MAPK1PKM
Hydrochloric Acid SCHEMBL7438235 0.82 MCHR1 (0.52) MEN1KMT2AALDH1A1HSD17B10MAPT
SCHEMBL7436155 0.81 MAPT (0.42) MEN1KMT2AALDH1A1MAPK1ALOX15
SCHEMBL7444066 0.81 MAPT (0.42) MEN1KMT2AALDH1A1MAPK1ALOX15
SCHEMBL14742925 0.81 KMT2A (0.62) MEN1KMT2AALDH1A1MAPK1ALOX15
SCHEMBL7436562 0.81 PTGS2 (0.45) MEN1KMT2AALDH1A1MAPTRAB9A
SCHEMBL7433535 0.79 MAPT (0.57) MEN1KMT2AALDH1A1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150119399-A1 BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2015-04-30 US claimed
EP-2804603-A1 BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE President and Fellows of Harvard College (US) 2014-11-26 EP claimed
WO-2013106547-A1 BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2013-07-18 WO claimed
US-7507707-B2 Methods of inducing ovulation using a non-polypeptide camp level modulator LABORATOIRES SERONO SA (CH) 2009-03-24 US claimed
EP-1849468-A2 Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist Nycomed GmbH (DE) 2007-10-31 EP claimed
US-20060079540-A1 Pde4 and pde3/4 inhibitors for use in the treatment of cachexia ALTANA PHARMA AG (DE) 2006-04-13 US claimed
EP-1567136-A1 PDE4 AND PDE3/4 INHIBITORS FOR USE IN THE TREATMENT OF CACHEXIA ALTANA Pharma AG (DE) 2005-08-31 EP claimed
US-20050112069-A1 Pharmaceutical composition of a pde4 or pde 3/4 inhibitor and histamine receptor antagonist NYCOMED GMBH (DE) 2005-05-26 US claimed
US-20050014762-A1 Combination NYCOMED GMBH (DE) 2005-01-20 US claimed
EP-1482938-A1 PHARMACEUTICAL COMPOSITION OF A PDE4 OR A PDE3/4 INHIBITOR AND A HISTAMINE RECEPTOR ANTAGONIST ALTANA Pharma AG (DE) 2004-12-08 EP claimed
EP-1418896-A2 ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION Vivus, Inc. (US) 2004-05-19 EP claimed
WO-2003074055-A1 PHARMACEUTICAL COMPOSITION OF A PDE4 OR A PDE3/4 INHIBITOR AND A HISTAMINE RECEPTOR ANTAGONIST ALTANA PHARMA AG (DE) 2003-09-12 WO claimed
WO-2003039552-A1 COMBINATION OF PDE4 OR PDE3/4 INHIBITOR AND AN ANTI-RHEUMATIC DRUG ALTANA PHARMA AG (DE) 2003-05-15 WO claimed
US-20030092706-A1 Combination NYCOMED GMBH (DE) 2003-05-15 US claimed
WO-2003024488-A2 COMBINATION OF A PDE INHIBITOR AND A LEUKOTRIENE RECEPTOR ANTAGONIST ALTANA PHARMA AG (DE) 2003-03-27 WO claimed
WO-2003000343-A2 ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION VIVUS, INC. (US) 2003-01-03 WO claimed
US-6156753-A Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction VIVUS, INC. (US) 2000-12-05 US claimed
EP-0506194-B1 4-aryl-thiazole or imidazole derivatives AKZO NOBEL NV (NL) 1996-08-21 EP claimed
US-5254575-A 4-aryl-thiazole derivatives AKZO N.V. (NL) 1993-10-19 US claimed
EP-0506194-A1 4-aryl-thiazole or imidazole derivatives Akzo Nobel N.V. (NL) 1992-09-30 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079540-A1 Pde4 and pde3/4 inhibitors for use in the treatment of cachexia PDE4A, PDE12, PDE4B MEN1 3248/4885KMT2A 1550/4885ALDH1A1 2365/4885
US-20150119399-A1 BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE IAPP, GPR119, PCNA MEN1 2249/4885KMT2A 3789/4885ALDH1A1 4758/4885
US-20050014762-A1 Combination PDE4A, PDE4B, PDE3B MEN1 4517/4885KMT2A 3112/4885ALDH1A1 1496/4885
US-20050112069-A1 Pharmaceutical composition of a pde4 or pde 3/4 inhibitor and histamine receptor antagonist HRH4, PDE4A, PDE4B MEN1 2922/4885KMT2A 894/4885ALDH1A1 1805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.